Affiliation: National Institutes of Health
- Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407Wanda L Salzer
Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
Pediatr Blood Cancer 59:834-9. 2012..Infants (<366 days of age) with acute lymphoblastic leukemia (ALL) have a poor prognosis. Most treatment failures occur within 6-9 months of diagnosis, primarily from relapse...
- Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: a report from the Children's Oncology GroupWanda L Salzer
NCI IRB, Building 82, Room 215, MSC 8200, Bethesda, MD 20892, USA
J Pediatr Hematol Oncol 34:e1-7. 2012..7 μM, compared with non-Hispanic children, 9.95 μM (P=0.0015), but this did not correlate with a difference in outcome. Neither RBC MTX, RBC folate, nor the RBC MTX:folate ratio identified children at increased risk of failure...
- Analysis of infectious complications in infants with acute lymphoblastic leukemia treated on the Children's Cancer Group Protocol 1953: a report from the Children's Oncology GroupWanda Salzer
National Cancer Institute, NIH, NCI IRB, 9030 Old Georgetown Road, Building 82, Room 215, MSC 8200, Bethesda, MD 20892, USA
J Pediatr Hematol Oncol 31:398-405. 2009....
- Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology groupW L Salzer
National Cancer Institute, Bethesda, MD 20892, USA
Leukemia 24:355-70. 2010..Only gender was prognostic in T-cell ALL. In infants, WBC and MLL translocation were linked to inferior outcome...